SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject10/27/2000 6:37:05 PM
From: nigel batesRead Replies (1) of 4974
 
RICHMOND, Va.--(BUSINESS WIRE)--Oct. 27, 2000--Insmed Incorporated (NASDAQ: INSM - news) today announced the pricing of a public offering of 6,500,000 shares of its common stock at a price of $11.875 per share. Of the 6,500,000 shares being offered, 5,500,000 shares are being offered by the Company and 1,000,000 shares are being offered by certain selling shareholders of Insmed.
The Company will not receive any of the proceeds from the sale of shares by the selling shareholders. The selling shareholders have granted the underwriters an option to purchase up to an additional 975,000 shares to cover over-allotments, if any. The underwriting is being managed by Robertson Stephens, Inc., with Banc of America Securities LLC, and Prudential Vector Healthcare Group, a unit of Prudential Securities, serving as co-managers.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext